Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Tempest Therapeutics Inc. (TPST:NASDAQ), powered by AI.
Tempest Therapeutics Inc. is currently trading at $1.25. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Tempest Therapeutics Inc. on Alpha Lenz.
View Tempest Therapeutics Inc.'s valuation metrics on Alpha Lenz.
“Tempest Therapeutics Inc.'s ROE is -203.6%. Explore profitability and growth together.”
Ask for details →Tempest Therapeutics Inc. is a biopharmaceutical company focused on developing innovative therapies designed to exploit the immune system for cancer treatment. Its primary function is the advancement of oncology programs centered on modulating key immune response pathways that are often dysregulated in cancer. Tempest Therapeutics targets various indications in the immune-oncology landscape, with a pipeline that includes both proprietary small molecules and therapeutic combinations. The company's research and development efforts emphasize precision medicine and the potential to treat a broad spectrum of tumor types, thus impacting cancer treatment strategies significantly. Tempest Therapeutics operates in a highly specialized sector characterized by rapid scientific advancements and regulatory processes, playing a significant role in the biotech industry's pursuit of groundbreaking cancer therapies.
“Tempest Therapeutics Inc.'s ROE is -203.6%. Explore profitability and growth together.”
Ask for details →Tempest Therapeutics Inc. (ticker: TPST) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 24 employees.
The current price is $1.25 with a P/E ratio of -x and P/B of -x.
ROE is -203.63%.